Shrink Nanotechnologies, BlackBox Semiconductor Sign Multi-Year License with University of Chicago

Shrink Nanotechnologies, Inc. ("Shrink") (OTC Bulletin Board: INKN), an innovative nanotechnology company developing products and licensing opportunities in the solar energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it had formed a wholly owned subsidiary called BlackBox Semiconductor, Inc. ("BlackBox"), and that BlackBox has entered into a worldwide multi-year exclusive license with the University of Chicago, licensing work based on Assistant Professor of Chemistry, Dmitri Talapin's "electronic glue" chemistry.  The license covers all applications except for thermoelectric applications.

"We are pleased to announce that we have reached an agreement with the University of Chicago to license intellectual property that we believe has the potential to radically change the economics in a number of burgeoning large industries, including printed semiconductors, roll-to-roll printed solar cells and a new generation of low cost printed nano-sensors.  This technology and the ongoing work by its inventors is widely acclaimed and has been published on multiple occasions in the world's most prestigious academic journals, including Science, Nature and the Journal of the American Chemical Society," said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

SHRINK NANOTECHNOLOGIES, INC. BLACKBOX SEMICONDUCTOR BlackBox Semiconductor Contributes to Investing in American Innovation.

Semiconductors have served as choice materials for many electronic and optical devices because of their physical properties.  Semiconductor nanocrystals are mass-produceable and have promise for use in device manufacturing via inkjet printing and other solution-based processes.

Commercial solar cells, computer chips and other semiconductor technologies typically use large semiconductor crystals, such as silicon.  These materials and the processes required to manufacture commercial products from them are expensive and can make large-scale applications such as rooftop solar-energy collectors prohibitive.  Also, material such as silicon is not "tunable" which means they can only harness a relatively narrow part of the available solar spectrum.

While semiconductor nanocrystals are very good receptors of light which could be converted to electricity (in the case of a solar cell), the collection of electrical charges from individual semiconductor nanocrystals cannot be accomplished efficiently using existing technologies because the semiconductor nanocrystals themselves are not great "carriers" of the electricity produced by the light they receive.

Prior to Dr. Talapin's innovation – which has been called "electronic glue" – nanocrystals were unable to efficiently transfer their electric charges to one another because of the surface ligands which are used in the nanocrystal synthesis process.  These surface ligands are bulky, insulating organic molecules that cap nanocrystals.  Dr. Talapin's "electronic glue" solves the ligand problem by substituted insulating organic molecules with novel inorganic molecules and dramatically increases the electronic coupling between nanocrystals.

Baum concluded, "We have been working on nanocrystal applications since we started Shrink.  We have an appreciation of the shortcomings of nanocrystals for these 'killer apps' like solar cells and other large market semiconductor applications.  We believe what we have is the potential to build low cost tunable solid state semiconductors which perform like bulk semiconductors, but which maintain all of the tremendous benefits that semiconductor nanocrystals offer.  This license is an important part of how we intend to drive value for our shareholders, as we build our business by executing on our unique model.  Over the coming months, we will begin to discuss this powerful technology and our plans to deploy resources to develop targeted commercial applications with it."

Source: http://www.shrinknano.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.